BDX stock touches 52-week low at $218.68 amid market shifts

Published 04/04/2025, 15:10
BDX stock touches 52-week low at $218.68 amid market shifts

Becton, Dickinson and Company’s (BDX) stock has reached a 52-week low, trading at $218.68, as investors navigate through a period of market volatility. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts setting price targets ranging from $245 to $325. The medical technology company, known for its wide range of medical supplies and devices, has experienced a notable decline over the past year. Despite the 13.42% decrease, BDX maintains strong fundamentals with a market capitalization of $61.4 billion and has raised its dividend for 54 consecutive years. The company’s stability is reflected in its low price volatility and expected net income growth this year. Investors are closely monitoring the company’s performance, looking for signs of a turnaround that could signal a rebound from the current lows. The company maintains healthy financials with a gross profit margin of 46.27% and steady revenue growth of 5.89% over the last twelve months.

In other recent news, BD (Becton, Dickinson and Company) announced the separation of its Biosciences and Diagnostic Solutions business, a move aimed at enhancing strategic focus and growth opportunities for both entities. The company emphasized that this decision aligns with its 2025 strategy to become a leading medical technology organization. Additionally, BD has commenced a clinical trial for its GalaFLEX LITE™ Scaffold, targeting improved outcomes in breast revision surgeries. This trial is a significant step toward obtaining FDA approval for the device, which aims to reduce capsular contracture recurrence.

In corporate governance updates, BD appointed Gregory J. Hayes to its board of directors. Hayes brings extensive experience from his previous roles, including his time as CEO of United Technologies Corporation (NYSE:RTX). Meanwhile, activist investor Starboard Value has reportedly acquired a stake in BD, advocating for the sale of the company’s life sciences division. This development reflects a broader trend of activist investors seeking to influence company strategies for shareholder value.

Furthermore, BD shareholders approved all board nominees during the recent annual meeting, reaffirming the company’s leadership structure. The appointment of Ernst & Young as the independent auditor for fiscal year 2025 was also ratified. These developments come as BD continues its strategic transformation, focusing on innovation and growth in the medical technology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.